Blueprint Medicines Corp. started an underwritten public offering of $275 million of its common stock.
The company intends to grant the underwriters an option to buy up to an additional $41.3 million of common shares.
Blueprint plans to use the net proceeds to fund certain clinical trials and the remaining proceeds for working capital and other general corporate purposes.
Goldman Sachs & Co. LLC, Morgan Stanley and Cowen are acting as joint book-running managers, while Canaccord Genuity is acting as co-manager for the offering.
